Sulfone COX-2 inhibitors increase susceptibility of human LDL and plasma to oxidative modification: Comparison to sulfonamide COX-2 inhibitors and NSAIDs

Atherosclerosis

Volumn 177, Issue 2, 2004, Pages 235-243

  Walter, Mary F ^a,c   Jacob, Robert F ^a   Day, Charles A ^a   Dahlborg, Rachel ^a   Weng, Yujia ^a   Mason, R Preston ^a,b  

^a ELUCIDA RESEARCH LLC   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Atherosclerosis; Inflammation; Lipoproteins

Indexed keywords

CELECOXIB; DICLOFENAC; ETORICOXIB; IBUPROFEN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MELOXICAM; NAPROXEN; ROFECOXIB; THIOBARBITURIC ACID REACTIVE SUBSTANCE; VALDECOXIB;

AEROBIC METABOLISM; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CONTROLLED STUDY; GENETIC SUSCEPTIBILITY; HUMAN; HUMAN CELL; HUMAN TISSUE; MASS SPECTROMETRY; OXIDATION; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; THROMBOSIS; X RAY DIFFRACTION;

ANIMALS; ANTIOXIDANTS; CHOLESTEROL, LDL; CHROMANS; CYCLOOXYGENASE INHIBITORS; DICLOFENAC; HUMANS; IBUPROFEN; ISOPROSTANES; ISOXAZOLES; LACTONES; NAPROXEN; OXIDATION-REDUCTION; PYRAZOLES; SULFONAMIDES; SULFONES; THIAZINES; THIAZOLES;

EID: 8644243944     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2004.10.001     Document Type: Article

References (36)

1. C. Bombardier, L. Laine, and A. Reicin Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis N Engl J Med 343 2000 120 128
2. F.E. Silverstein, G. Faich, and J.L. Goldstein Gastrointestinal toxicity with celecoxib vs. nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the celecoxib long-term arthritis safety study (CLASS): a randomized control trial JAMA 284 2000 1247 1255
3. U. Schoenbeck, G.K. Sukhova, and P. Graber Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions Am J Pathol 155 1999 1281 1291
4. C.S. Baker, R.J. Hall, and T.J. Evans Cyclooxygenase-2 is widely expressed in atherosclerotic lesions affecting native and transplanted human coronary arteries and colocalizes with inducible nitric oxide synthase and nitrotryrosine particularly in macrophages Arterioscler Thromb Vasc Biol 19 1999 646 655
5. G.A. FitzGerald, B. Smith, A.K. Pedersen, and A.R. Brash Increased prostacylin biosynthesis in patients with severe atherosclerosis and platelet activation N Engl J Med 310 1984 1065 1068
6. Y. Cheng, S.C. Austin, and B. Rocca Role of prostacyclin in the cardiovascular response to thromboxane A2 Science 296 2002 539 541
7. D. Mukherjee, S.T. Nissen, and E.J. Topol Risk of cardiovascular events associated with selective COX-2 inhibitors JAMA 286 2000 954 959
8. W.A. Ray, C.M. Stein, and J.R. Daugherty COX-2 selective non-steroidal anti- inflammatory drugs and risk of serious coronary heart disease Lancet 360 2002 1071 1073
9. D.H. Solomon, S. Schneeweiss, and R.J. Glynn Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults Circulation 109 2004 2068 2073
10. M. Mamdani, D.N. Juurlink, and D.S. Lee Cyclo-oxygenase-2 inhibitors versus non- selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study Lancet 363 2004 1751 1756
11. J.R. Vane Back to an aspirin a day? Science 296 2002 474 475
12. V. Schächinger, M.B. Britten, and A.M. Zeiher Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease Circulation 101 2000 1899 1906
13. R. Chenevard, D. Hurlimann, and M. Bechir Selective COX-2 inhibition improves endothelial function in coronary artery disease Circulation 107 2003 405 409
14. M. Hermann, G. Camici, and A. Fratton Differential effects of selective cyclooxygenase-2 inhibitors on endothelial function in salt-induced hypertension Circulation 2003 108
15. D. Monakier, M. Mates, and M.W. Klutstein Rofecoxib, a COX-2 inhibitor, lowers c-reactive protein and interleukin-6 levels in patients with acute coronary syndromes Chest 125 2004 1610 1615
16. J.L. Witztum, and J.A. Berliner Oxidized phospholipids and isoprostanes in atherosclerosis Curr Opin Lipidol 9 1998 441 448
17. D. Steinberg Low density lipoprotein oxidation and its pathobiological significance J Biol Chem 272 1997 20963 20966
18. K. Nishi, H. Itabe, and M. Uno Oxidized LDL in carotid plaques and plasma associates with plaque instability Arterioscler Thromb Vasc Biol 22 2002 1649 1654
19. S. Ehara, M. Ueda, and T. Naruko Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes Circulation 103 2001 1955
20. B.H. Chung, J.P. Segrest, and M.J. Ray Single vertical spin density gradient ultracentrifugation Methods Enzymol 128 1986 181 208
21. U.K. Laemmli Cleavage of structural proteins during the assembly of the head of bacteriophage Nature 227 1970 680 686
22. I.T. Mak, and W.B. Weglicki Antioxidant properties of calcium channel blocking drugs Methods Enzymol 234 1994 620 630
23. H. Esterbauer, G. Striegl, H. Puhl, and M. Rotheneder Continuous monitoring of in vitro oxidation of human low density lipoprotein Free Radic Res Commun 6 1989 67 75
24. D.J. Hennessy, G.R. Reid, F.E. Smith, and S.L. Thompson Ferene- a new spectrophotometric reagent for iron Can J Chem 62 1985 721 724
25. A.D. Bangham, M.M. Standish, and J.C. Watkins Diffusion of univalent ions across the lamellae of swollen phospholipids J Mol Biol 13 1965 238 252
26. M.F. Walter, J.B. Blumberg, G.G. Dolnikowski, and G.J. Handelman Streamlined F2-isoprostane analysis in plasma and urine with high-performance liquid chromatography and gas chromatography/mass spectroscopy Anal Biochem 280 2000 73 79
27. D. Huang, B. Ou, M. Hampsch-Woodill, J.A. Flanagan, and R.L. Prior High-throughput assay of oxygen radical absorbance capacity (ORAC) using a multichannel liquid handling system coupled with a microplate fluorescence reader in 96-well format J Agric Food Chem 50 2002 1815 1821
28. D.W. Chester, L.G. Herbette, and R.P. Mason Diffusion of dihydropyridine calcium channel antagonists in cardiac sarcolemmal lipid multibilayers Biophys J 52 1987 1021 1030
29. R.P. Mason, G.E. Gonye, D.W. Chester, and L.G. Herbette Partitioning and location of Bay K 8644, 1,4-dihydropyridine calcium channel agonist, in model and biological membranes Biophys J 55 1989 769 778
30. D. Steinberg, S. Parthasarathy, and T.E. Carew Beyond cholesterol. Modifications of low- density lipoprotein that incease its atherogenicity N Engl J Med 320 1989 915 924
31. U.P. Steinbrecher, M. Lougheed, W.C. Kwan, and M. Dirks Recognition of oxidized low density lipoprotein by the scavenger receptor of macrophages results from derivatization of apolipoprotein B by products of fatty acid peroxidation J Biol Chem 264 1989 15216 15223
32. R.P. Mason, and R.F. Jacob X-ray diffraction analysis of membrane structure changes with oxidative stress D. Armstrong Methods in molecular biology: ultrastructural and molecular biology protocols 2002 Humana Press Inc Totowa, NJ 71 80
33. T.N. Tulenko, M. Chen, P.E. Mason, and R.P. Mason Physical effects of cholesterol on arterial smooth muscle membranes: Evidence of immiscible cholesterol domains and alterations in bilayer width during atherogenesis J Lipid Res 39 1998 947 956
34. R.P. Mason, M.F. Walter, and P.E. Mason Effect of oxidative stress on membrane structure: Small angle X-ray diffraction analysis Free Radic Biol Med 23 1997 419 425
35. 2 synthase-1 Nature 367 1994 243 249
36. 2-isoprostanes in human atherosclerotic lesions J Clin Invest 100 1997 2028 2034